Novo Nordisk A/S
Bagsværd, Denmark, 10 February 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name of the Board member/Executive/Associated Person
Martin Holst Lange
2
Reason for the notification
a)
Position/status
Executive Vice President, R&D and Chief Scientific Officer (CSO)
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer
a)
Name
Novo Nordisk A/S
b)
LEI
549300DAQ1CVT6CXN342
4
Details of the transaction(s)
a)
Description of the financial instrument,
type of instrument,
Shares
Identification code
Novo Nordisk B DK0062498333
b)
Nature of the transaction
Sale of shares (to cover tax on shares transferred in accordance with Long Term Incentive programme)
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 319.80
22,000
d)
Aggregated information
22,000 shares
DKK 7,035,600
e)
Date of the transaction
2026-02-09
f)
Place of the transaction
Nasdaq Copenhagen
About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
Company announcement No 09 / 2026